AGN Posts Solid Q4 Results, Guidance Conservative
Analysts at Leerink Swann & Co maintain their "outperform" rating on Allergan Inc (NYSE: AGN).
Allergan has reported its Q4 EPS marginally ahead of the consensus and inline with the estimates. AGN continues to invest in SG&A and R&D while posting solid results, the analysts say. Regarding 2010 outlook, the analysts say that, “AGN is well positioned to beat-and-raise during the year after demonstrating its strength with a couple of very solid Q's recently.”
“AGN is one of the best positioned companies in aesthetics with deep pockets and a broad portfolio of products to leverage including Botox, Juvederm, breast implants and Latisse,” the analysts say. “In addition to aesthetics, AGN is well diversified with strong franchises in ophthalmology and obesity, with key growth drivers such as Ozurdex, Restasis and Combigan that could help offset some near-term challenges with the aesthetics products as a result of the weakened global economy,” Leerink Swann & Co adds.
